MCID: ADR040
MIFTS: 46

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15 17
Pheochromocytoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 71 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 A malignant pheochromocytoma that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to malignant pediatric adrenal gland pheochromocytoma and pheochromocytoma, and has symptoms including fever, tremor and abdominal pain. An important gene associated with Adrenal Gland Pheochromocytoma is NGF (Nerve Growth Factor), and among its related pathways/superpathways is Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Angiotensin II and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, adrenal gland and testes.

Related Diseases for Adrenal Gland Pheochromocytoma

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


fever, tremor, abdominal pain, chest pain, headache

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
8
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
9 Adrenergic beta-Agonists Phase 4
10 Adrenergic Agents Phase 4
11 Adrenergic Agonists Phase 4
12 Neurotransmitter Agents Phase 4
13 Antihypertensive Agents Phase 4
14 Vasodilator Agents Phase 4
15 Angiotensinogen Phase 4
16 Angiotensin Receptor Antagonists Phase 4
17 Giapreza Phase 4
18 Dopamine agonists Phase 4
19 Antiparkinson Agents Phase 4
20 Angiotensin II Type 1 Receptor Blockers Phase 4
21 Antidepressive Agents Phase 4
22 Psychotropic Drugs Phase 4
23 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
24 Duloxetine Hydrochloride Phase 4
25 Serotonin Uptake Inhibitors Phase 4
26
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
27
Tyramine Investigational, Nutraceutical Phase 4 51-67-2 5610
28
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
29
Lenograstim Approved, Investigational Phase 3 135968-09-1
30
Ifosfamide Approved Phase 3 3778-73-2 3690
31
Dexmedetomidine Approved, Vet_approved Phase 3 113775-47-6 5311068 68602
32
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
33 Calamus Phase 3
34
Liposomal doxorubicin Phase 3 31703
35
Isophosphamide mustard Phase 3 0
36 Anti-Bacterial Agents Phase 3
37 Antibiotics, Antitubercular Phase 3
38 Pharmaceutical Solutions Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Anesthetics, General Phase 3
41 Hypnotics and Sedatives Phase 3
42 Anti-Arrhythmia Agents Phase 3
43 Anticonvulsants Phase 3
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
48
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
49
Carbidopa Approved Phase 2 28860-95-9 34359
50 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
2 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
3 Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
4 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
5 Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males Recruiting NCT03249311 Phase 4 Levomilnacipran;Duloxetine;Placebos
6 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
7 An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
8 High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
12 Magnesium Sulfate Versus Dexmedetomidine on Anesthesia Awakening. Randomized Clinical Trial. Not yet recruiting NCT04300985 Phase 3 Dexmedetomidine;Sham treatment;Magnesium Sulfate
13 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
14 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
16 A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma Completed NCT01635907 Phase 2 Dovitinib
17 A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
18 (131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
19 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
20 A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors Completed NCT00923481 Phase 2 Fostamatinib disodium
21 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
22 A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer Completed NCT03165721 Phase 2 SGI-110 (guadecitabine)
23 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
24 A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
25 Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder Completed NCT02437383 Phase 2 Propranolol ER;Placebo
26 A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors Completed NCT00566995 Phase 2 ZACTIMA (Vandetanib) (ZD6474)
27 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
28 Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors Recruiting NCT00107289 Phase 2
29 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
30 The Perioperative Use of Dexmedetomidine and Magnesium Sulfate Compared With Traditional Anesthetic Technique for Open Resection of Pheochromocytoma. Recruiting NCT04320589 Phase 2 Dexmedetomidine;General anesthetic
31 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
32 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
33 Lidocaine Infusion in Functional Endoscopic Sinus Surgery Recruiting NCT03047070 Phase 2 Lidocaine;Normal saline
34 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib S-malate
35 Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and / or Symptomatic Tumors With Somatostatin Receptor Overexpression Recruiting NCT04029428 Phase 2 90Y-DOTATATE;(177Lu-DOTAOTyr3)Octreotate;90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
36 Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Recruiting NCT04074135 Phase 2 68-Gallium DOTATATE
37 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
38 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
39 Phase II Trial of LBlOO, a Protein Phosphatase 2A Inhibitor, in Recurrent Gliomas Recruiting NCT03027388 Phase 2 LB-100
40 Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma Active, not recruiting NCT03008369 Phase 2 Lenvatinib
41 A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
42 A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
43 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
44 A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma Not yet recruiting NCT04394858 Phase 2 Olaparib;Temozolomide
45 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
46 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
47 Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
48 A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored, Study to Determine the Safety and Effectiveness of 177LuDOTATOC in Adult Subjects With STTR(+) Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus Neuroendocrine Tumors (PUTNET) Not yet recruiting NCT04276597 Phase 2 177Lu-DOTATOC
49 Phase I/II Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3 OCTREOTATE (177Lu-DOTATATE) in Children With Neuroendocrine Tumor, Neuroblastoma, or Pheochromocytoma/Paraganglioma Not yet recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
50 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Not yet recruiting NCT04284774 Phase 2 Tipifarnib

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Metyrosine
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Propranolol
Propranolol Hydrochloride

Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

40
Thyroid, Adrenal Gland, Testes, Heart, Brain, Pituitary, Liver

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

(show top 50) (show all 15483)
# Title Authors PMID Year
1
Knocking down TRPM2 expression reduces cell injury and NLRP3 inflammasome activation in PC12 cells subjected to oxygen-glucose deprivation. 61
32394974 2020
2
Laparoscopic excision of a large Adrenal Ganglioneuroma masquerading as Pheochromocytoma- A case report & review of literature. 61
32489900 2020
3
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study. 61
32413902 2020
4
miR-211-5p alleviates focal cerebral ischemia-reperfusion injury in rats by down-regulating the expression of COX2. 61
32311346 2020
5
Antiangiogenic therapies for pheochromocytoma and paraganglioma. 61
32369773 2020
6
Stemness regulation of the adrenal mixed corticomedullary tumorigenesis-a case-control study. 61
32438306 2020
7
Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K+ current and α-methylglucoside-induced current in pituitary tumor (GH3) and pheochromocytoma PC12 cells. 61
32353360 2020
8
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial. 61
31714582 2020
9
True Picomolar Neurotransmitter Sensor Based on Open-Ended Carbon Nanotubes. 61
32406234 2020
10
Retrospective comparison of three minimally invasive approaches for adrenal tumors: perioperative outcomes of transperitoneal laparoscopic, retroperitoneal laparoscopic and robot-assisted laparoscopic adrenalectomy. 61
32517679 2020
11
Genetic screening for monogenic hypertension in hypertensive individuals in a clinical setting. 61
32561571 2020
12
The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. 61
32533054 2020
13
Cadmium induces mitophagy via AMP-activated protein kinases activation in a PINK1/Parkin-dependent manner in PC12 cells. 61
32396704 2020
14
Investigation and comparison of the protective activities of three functional proteins-lactoferrin, α-lactalbumin, and β-lactoglobulin-in cerebral ischemia reperfusion injury. 61
32229112 2020
15
MiR-429/200a/200b negatively regulate Notch1 signaling pathway to suppress CoCl2-induced apoptosis in PC12 cells. 61
32004541 2020
16
Malaysian macroalga Padina australis Hauck attenuates high dose corticosterone-mediated oxidative damage in PC12 cells mimicking the effects of depression. 61
32489279 2020
17
The protective effects of moscatilin against methylglyoxal-induced neurotoxicity via the regulation of p38/JNK MAPK pathways in PC12 neuron-like cells. 61
32325188 2020
18
Not all laparoscopic adrenalectomies are equal: analysis of postoperative outcomes based on tumor functionality. 61
32495185 2020
19
A rare long-term undetected pheochromocytoma leading to Takotsubo syndrome in an older male patient: a case report. 61
32576166 2020
20
Intraoperative hypotension is associated with increased postoperative complications in patients undergoing surgery for pheochromocytoma-paraganglioma: a retrospective cohort study. 61
32532209 2020
21
Structure Engineering of a Lanthanide-Based Metal-Organic Framework for the Regulation of Dynamic Ranges and Sensitivities for Pheochromocytoma Diagnosis. 61
32337783 2020
22
Mitigating effect of paxilline against injury produced by Cd2+ in rat pheochromocytoma PC12 and ascites hepatoma AS-30D cells. 61
32244116 2020
23
Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. 61
32498673 2020
24
History of the multiple endocrine neoplasia workshops and overview of MEN2019. 61
32508314 2020
25
Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. 61
32521546 2020
26
Targeting Pheochromocytoma/Paraganglioma with polyamine inhibitors. 61
32562798 2020
27
Case report of a phantom pheochromocytoma. 61
32550819 2020
28
The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. 61
32486832 2020
29
VHL-RELATED NEUROENDOCRINE NEOPLASMS AND BEYOND: AN ISRAELI SPECIALIZED CENTER REAL-LIFE REPORT. 61
32576040 2020
30
Moderate renal impairment does not preclude the accuracy of 24-hour urine normetanephrine measurements for suspected pheochromoctyoma. 61
32133686 2020
31
Right robot-assisted partial adrenalectomy for pheochromocytoma with video. 61
32198067 2020
32
Predictors of hemodynamic instability in patients with pheochromocytoma and paraganglioma. 61
32562589 2020
33
A case of pheochromocytoma presenting with cardiac manifestation: case report. 61
32552769 2020
34
Reversible renal infarctions associated with pheochromocytoma: a case report. 61
32496301 2020
35
A case report of rare ectopic pheochromocytoma adjacent to pancreas. 61
32569235 2020
36
Catecholamine-induced Myocarditis in a Child with Pheochromocytoma 61
31208160 2020
37
[Recurrent Takotsubo syndrome associated with pheochromocytoma: a case report]. 61
32486588 2020
38
Management of acute limb ischemia related to underlying pheochromocytoma. 61
32510032 2020
39
MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression. 61
32511227 2020
40
The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma. 61
32303954 2020
41
Aggressive Paraganglioma of the Urinary Bladder with Local Recurrence and Pelvic Metastasis. 61
32548698 2020
42
High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. 61
32250976 2020
43
A novel Double <i>RET</i> E768D/L790F mutation associated with a MEN2B-like phenotype. 61
32546069 2020
44
Pheochromocytoma and Paraganglioma. 61
32571511 2020
45
Activation of protein kinase R in the manganese-induced apoptosis of PC12 cells. 61
32574669 2020
46
NMMHC IIA triggers neuronal autophagic cell death by promoting F-actin-dependent ATG9A trafficking in cerebral ischemia/reperfusion. 61
32513915 2020
47
Neuropathy-associated histidyl-tRNA synthetase variants attenuate protein synthesis in vitro and disrupt axon outgrowth in developing zebrafish. 61
32543048 2020
48
Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. 61
32337341 2020
49
Approach to patients with bilateral adrenal incidentalomas. 61
32209820 2020
50
Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. 61
31834447 2020

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9 (show top 50) (show all 190)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88294223 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 6
2 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 6
3 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 6
4 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 6
5 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 6
6 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 6
7 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 6
8 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 6
9 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 6
10 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 6
11 COSM88306166 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 6
12 COSM88299307 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 6
13 COSM88205586 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 6
14 COSM87898351 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
15 COSM87955161 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 6
16 COSM92347003 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 6
17 COSM92347226 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 6
18 COSM93656552 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.G629R 17:31225134-31225134 6
19 COSM93692982 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 6
20 COSM93650970 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 6
21 COSM93657331 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 6
22 COSM93646872 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 6
23 COSM93662933 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 6
24 COSM93654948 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 6
25 COSM93650764 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 6
26 COSM93652933 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.? 17:31159009-31159009 6
27 COSM93668028 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 6
28 COSM93647950 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.? 17:31221932-31221932 6
29 COSM93688082 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 6
30 COSM93680586 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 6
31 COSM93687360 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 6
32 COSM93653832 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.? 17:31227607-31227607 6
33 COSM88844097 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 6
34 COSM88849124 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 6
35 COSM88850455 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 6
36 COSM87668405 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.8764C>T p.R2922W 12:49038592-49038592 6
37 COSM87676802 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.15666C>A p.N5222K 12:49026300-49026300 6
38 COSM87654373 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.15668A>G p.N5223S 12:49026298-49026298 6
39 COSM87697808 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.8203G>A p.G2735S 12:49039461-49039461 6
40 COSM87681614 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7829T>C p.L2610P 12:49039941-49039941 6
41 COSM87715792 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.12664C>G p.L4222V 12:49032041-49032041 6
42 COSM87718583 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7607T>C p.F2536S 12:49040163-49040163 6
43 COSM112988851 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 6
44 COSM112988925 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 6
45 COSM112988832 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 6
46 COSM95516578 H3-3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 6
47 COSM93760866 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.2530C>T p.R844C 20:58909365-58909365 6
48 COSM107493928 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1731C>A p.N577K 8:38417331-38417331 6
49 COSM86761750 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1104G>A p.M368I 2:46376608-46376608 6
50 COSM86762542 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1588G>C p.A530P 2:46380260-46380260 6

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.01 NGF MIR210 BDNF

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neuron differentiation GO:0045664 9.43 NGF BDNF
2 negative regulation of apoptotic signaling pathway GO:2001234 9.4 MIR210 BDNF
3 positive regulation of macroautophagy GO:0016239 9.37 TRIM13 BNIP3
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.32 NGF BDNF
5 nerve development GO:0021675 9.26 NGF BDNF
6 nerve growth factor signaling pathway GO:0038180 9.16 NGF BDNF
7 positive regulation of collateral sprouting GO:0048672 8.96 NGF BDNF
8 peripheral nervous system development GO:0007422 8.8 SERPINI1 NGF BDNF

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor receptor binding GO:0005163 8.62 NGF BDNF

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....